wire - news in brief
Category
Results 301 - 350 of 395.
Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
Pivotal phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS congress 2019 74% reduction in the risk of relapse for s
Pivotal phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS congress 2019 74% reduction in the risk of relapse for s
Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) Roche today announced positive data from the Phase III IM
Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) Roche today announced positive data from the Phase III IM
A smart artificial hand for amputees merges user and robotic control
EPFL scientists have successfully tested new neuroprosthetic technology that combines robotic control with users' voluntary control, opening avenues in the new interdisciplinary field of shared control for neuroprosthetic technologies. EPFL scientists are developing new approaches for improved control of robotic hands - in particular for amputees - that combines individual finger control and automation for improved grasping and manipulation.
EPFL scientists have successfully tested new neuroprosthetic technology that combines robotic control with users' voluntary control, opening avenues in the new interdisciplinary field of shared control for neuroprosthetic technologies. EPFL scientists are developing new approaches for improved control of robotic hands - in particular for amputees - that combines individual finger control and automation for improved grasping and manipulation.
Next Monday, the Fall Semester begins for about 27,000 students at the University of Zurich. The number of Master's students in particular has increased.
This weekend in Yverdon, the HydroContest EPFL Team took first place in the nautical competition with its lightweight boat, second place in endurance, and third place in speed with its heavyweight boat.
Approach and landing are among the most complex phases of a flight.
Climate protection thanks to agroforestry
Zurich-Reckenholz, 10.09.2019 - Producing food and feed while protecting the climate - is that possible? Yes, and agroforestry is one option, combining agriculture and wood production on the same land.
Zurich-Reckenholz, 10.09.2019 - Producing food and feed while protecting the climate - is that possible? Yes, and agroforestry is one option, combining agriculture and wood production on the same land.
Today the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland and OSYPKA AG/OSYPKA Medtec, Rheinfelden, Germany and Longmont, Colorado, USA, announced a collaboration to develop and integrate innovative technologies into implantable neuro-devices.
Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future disability outcomes Separate analyses presented from one of the first studies to demonstrate NfL levels are correlated with active MRI lesions in PPMS Roche today announced new data from OCREVUS (ocrelizumab) trials in relapsing and primary progressive multiple sclerosis (MS).
Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future disability outcomes Separate analyses presented from one of the first studies to demonstrate NfL levels are correlated with active MRI lesions in PPMS Roche today announced new data from OCREVUS (ocrelizumab) trials in relapsing and primary progressive multiple sclerosis (MS).
Universities play an increasingly important role in society creating an environment where talents, like graduate student David Yenicelik, thrive.
Novartis data confirm long-term efficacy and safety of Aimovig for majority of patients with episodic migraine
The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years
The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years
European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stag
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stag
Vontobel Award: Systematic Remembering and Similar Surgical Consequences
This year's Vontobel Award for Research on Age(ing) goes to Burcu Demiray Batur from the University of Zurich, Jonathan Rychen from the University Hospital of Basel and Sarah Stricker from the Hôpital Necker in Paris.
This year's Vontobel Award for Research on Age(ing) goes to Burcu Demiray Batur from the University of Zurich, Jonathan Rychen from the University Hospital of Basel and Sarah Stricker from the Hôpital Necker in Paris.
EPFL will open its doors to the public on 14-15 September as it celebrates its 50th year as a federal institute of technology.
She was involved in developing the world's most accurate clock, and now she helps companies adopt more sustainable business practices: Petrissa Eckle, Executive Director of the Sustainability in Business Lab at ETH Zurich.
Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS
Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder New data provide insights into neuro
Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder New data provide insights into neuro
ERC Starting Grants 2019 for ETHZ
Fifteen talented young researchers from ETH Zurich are each to receive an ERC Starting Grant, which is more than for any year previously.
Fifteen talented young researchers from ETH Zurich are each to receive an ERC Starting Grant, which is more than for any year previously.
Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients ; EVALUATE-HF results complement findings PROVE-HF establishes significant correlation between improvement in widely used cardiac biomarker and positive changes in heart structure and ability to pump blood in patients taking Entresto Safety and tole
Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients ; EVALUATE-HF results complement findings PROVE-HF establishes significant correlation between improvement in widely used cardiac biomarker and positive changes in heart structure and ability to pump blood in patients taking Entresto Safety and tole
Positive phase III results show Xofluza reduces risk of developing flu after contact with an infected person by 86%
BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo Xofluza may represent an
BLOCKSTONE study reaches primary endpoint of fewer people testing positive for flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo Xofluza may represent an
Roche presents positive phase III study results for one-dose Xofluza in children with flu
Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose
Phase III MINISTONE-2 data are consistent with known safety profile of Xofluza (baloxavir marboxil) in children and show comparable efficacy to oseltamivir Xofluza was administered as a new one-dose
Novartis PARAGON-HF trial suggests Entresto benefit in HFpEF patients but narrowly misses primary endpoint
Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.059) Totality of evidence, including improvement in various measures of symptoms, quality of life, and renal function, suggests clinically important benefits in HFpEF Entresto was well tolerated and the overall safety profile was comparable
Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.059) Totality of evidence, including improvement in various measures of symptoms, quality of life, and renal function, suggests clinically important benefits in HFpEF Entresto was well tolerated and the overall safety profile was comparable
Medicine for tomorrow
How can the latest findings from materials science be used in medical practice to develop innovative diagnostic and therapeutic concepts' Empa researchers, physicians from the Cantonal Hospital of St
How can the latest findings from materials science be used in medical practice to develop innovative diagnostic and therapeutic concepts' Empa researchers, physicians from the Cantonal Hospital of St
Until a few years ago, experts in Switzerland spoke of around 20 species. Now a major project by Eawag, the University of Zurich, the Swiss Centre for the Cartography of the Fauna (CSCF) and the Swiss Entomological Society (SEG) has researched over 40 clearly different species.
Novartis ofatumumab demonstrates superiority versus Aubagio in two head-to-head Phase III multiple sclerosis studies
In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio * (teriflunomide) in patients with relapsing forms of MS (RMS) Key secondary endpoi
In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio * (teriflunomide) in patients with relapsing forms of MS (RMS) Key secondary endpoi
ETH+: Five further initiatives selected
In the second round of ETH+, the Executive Board's funding instrument for new research ideas and exchange between disciplines and departments, five new initiatives were selected.
In the second round of ETH+, the Executive Board's funding instrument for new research ideas and exchange between disciplines and departments, five new initiatives were selected.
After studying biology and biochemistry at the University of Lorraine (Metz, F), Benoît Ferrari worked on the ecotoxicity of solid waste in his dissertation.
This Friday, 30 August, a team of EPFL students will take part in the SensUs competition at the Eindhoven University of Technology.
Quantum computers and the future of computation
Are there limits to what computers are actually able to compute, and do quantum computers really solve more problems than conventional computers' Computer scientist Scott Aaronson will discuss these kinds of fundamental questions during the Paul Bernays Lectures 2019. In 2007, something unusual happened: an ad spot ran on Australian TV that involved two models in a dressing room discussing quantum mechanics.
Are there limits to what computers are actually able to compute, and do quantum computers really solve more problems than conventional computers' Computer scientist Scott Aaronson will discuss these kinds of fundamental questions during the Paul Bernays Lectures 2019. In 2007, something unusual happened: an ad spot ran on Australian TV that involved two models in a dressing room discussing quantum mechanics.
